BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,063 filers reported holding BAXTER INTL INC in Q3 2018. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $208,000 | -64.1% | 2,697 | -65.6% | 0.01% | -66.7% |
| Q2 2018 | $580,000 | +5.6% | 7,851 | -7.0% | 0.02% | 0.0% |
| Q1 2018 | $549,000 | -4.4% | 8,440 | -5.1% | 0.02% | 0.0% |
| Q4 2017 | $574,000 | +4.0% | 8,892 | +1.0% | 0.02% | -10.0% |
| Q3 2017 | $552,000 | +3.8% | 8,804 | +0.3% | 0.02% | -4.8% |
| Q2 2017 | $532,000 | +100.8% | 8,782 | +71.9% | 0.02% | +90.9% |
| Q1 2017 | $265,000 | -73.3% | 5,108 | -83.1% | 0.01% | -82.0% |
| Q3 2015 | $992,000 | -67.5% | 30,190 | -30.9% | 0.06% | -65.9% |
| Q2 2015 | $3,053,000 | +5.1% | 43,660 | +2.9% | 0.18% | +3.5% |
| Q1 2015 | $2,906,000 | -3.8% | 42,424 | +2.9% | 0.17% | -6.0% |
| Q4 2014 | $3,022,000 | +5.7% | 41,233 | +3.5% | 0.18% | -1.1% |
| Q3 2014 | $2,860,000 | -5.7% | 39,853 | -5.0% | 0.19% | -7.9% |
| Q2 2014 | $3,034,000 | +5.4% | 41,969 | +7.2% | 0.20% | -1.9% |
| Q1 2014 | $2,879,000 | +28.3% | 39,133 | +21.3% | 0.21% | +16.4% |
| Q4 2013 | $2,244,000 | +201.2% | 32,261 | +184.3% | 0.18% | +160.3% |
| Q3 2013 | $745,000 | +21.5% | 11,348 | +28.3% | 0.07% | +4.6% |
| Q2 2013 | $613,000 | – | 8,845 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |